{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T17:23:00Z","timestamp":1704302580492},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,10,18]],"date-time":"2015-10-18T00:00:00Z","timestamp":1445126400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s00108-015-3705-0","type":"journal-article","created":{"date-parts":[[2015,10,19]],"date-time":"2015-10-19T00:32:48Z","timestamp":1445214768000},"page":"1255-1263","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Neue Antibiotika auf dem Markt und in Entwicklung"],"prefix":"10.1007","volume":"56","author":[{"given":"W.V.","family":"Kern","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,18]]},"reference":[{"key":"3705_CR1","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1128\/AAC.00099-14","volume":"58","author":"Almaghrabi","year":"2014","unstructured":"Almaghrabi R, Clancy CJ, Doi Y et\u00a0al (2014) Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Antimicrob Agents Chemother 58:4443\u20134451","journal-title":"Antimicrob Agents Chemother"},{"key":"3705_CR2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciu219","volume":"59","author":"Awad","year":"2014","unstructured":"Awad SS, Rodriguez AH, Chuang YC et\u00a0al (2014) A phase\u00a03 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis 59:51\u201361","journal-title":"Clin Infect Dis"},{"key":"3705_CR3","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1128\/AAC.04376-14","volume":"59","author":"Chan","year":"2015","unstructured":"Chan LC, Basuino L, Dip EC, Chambers\u00a0HF (2015) Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 59(6):3252\u20133256","journal-title":"Antimicrob Agents Chemother"},{"key":"3705_CR4","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1128\/AAC.00826-13","volume":"58","author":"Drawz","year":"2014","unstructured":"Drawz SM, Papp-Wallace KM, Bonomo RA (2014) New \u03b2-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 58:1835\u20131846","journal-title":"Antimicrob Agents Chemother"},{"key":"3705_CR5","unstructured":"Dryden M, Wilson D, Iaconis J, Gonzalez\u00a0J (2015) A phase\u00a0III trial of ceftaroline fosamil 600\u00a0mg q8\u00a0h versus vancomycin plus aztreonam in patients with cSSTI with systemic inflammatory response or underlying comorbidities. 25th ECCMID, Kopenhagen. Abstract O193"},{"key":"3705_CR6","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1586\/14787210.2015.1068118","volume":"13","author":"Henson","year":"2015","unstructured":"Henson KE, Levine MT, Wong EA, Levine\u00a0DP (2015) Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile. Expert Rev Anti Infect Ther 13:1265\u20131278","journal-title":"Expert Rev Anti Infect Ther"},{"key":"3705_CR7","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/cid\/civ478","volume":"61","author":"Hook","year":"2015","unstructured":"Hook EW 3rd, Golden M, Jamieson BD et\u00a0al (2015) A phase\u00a02 trial of oral solithromycin 1200\u00a0mg or 1000\u00a0mg as single-dose oral therapy for uncomplicated gonorrhea. Clin Infect Dis 61:1043\u20131048","journal-title":"Clin Infect Dis"},{"key":"3705_CR8","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.drudis.2014.12.003","volume":"20","author":"Ivarsson","year":"2015","unstructured":"Ivarsson ME, Leroux JC, Castagner B (2015) Investigational new treatments for Clostridium difficile infection. Drug Discov Today 20(5):602\u2013608","journal-title":"Drug Discov Today"},{"key":"3705_CR9","doi-asserted-by":"crossref","unstructured":"Jacobsson S, Golparian D, Phan LT et\u00a0al (2015) In vitro activities of the novel bicyclolides modithromycin (EDP-420, EP-013420, S-013420) and EDP-322 against MDR clinical Neisseria gonorrhoeae isolates and international reference strains. J\u00a0Antimicrob Chemother 70:173\u2013177","DOI":"10.1093\/jac\/dku344"},{"key":"3705_CR10","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40262-015-0281-3","volume":"54","author":"Kiang","year":"2015","unstructured":"Kiang TK, Wilby KJ, Ensom MH (2015) A critical review on the clinical pharmacokinetics, pharmacodynamics, and clinical trials of ceftaroline. Clin Pharmacokinet 54:915\u2013931","journal-title":"Clin Pharmacokinet"},{"key":"3705_CR11","doi-asserted-by":"crossref","first-page":"6534","DOI":"10.2174\/13816128113199990494","volume":"19","author":"Lee","year":"2013","unstructured":"Lee CR, Lee JH, Jeong BC, Lee\u00a0SH (2013) Lipid\u00a0A biosynthesis of multidrug-resistant pathogens \u2013 a novel drug target. Curr Pharm Des 19(36):6534\u20136350","journal-title":"Curr Pharm Des"},{"key":"3705_CR12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nature14098","volume":"517","author":"Ling","year":"2015","unstructured":"Ling LL, Schneider T, Peoples AJ et\u00a0al (2015) A new antibiotic kills pathogens without detectable resistance. Nature 517:455\u2013459","journal-title":"Nature"},{"key":"3705_CR13","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1128\/AAC.00504-15","volume":"59","author":"Louie","year":"2015","unstructured":"Louie T, Nord CE, Talbot GH et\u00a0al (2015) A multicenter, double-blind, randomized, phase\u00a02 study evaluating the novel antibiotic, cadazolid, in patients with Clostridium difficile infection. Antimicrob Agents Chemother 59:6266\u20136273","journal-title":"Antimicrob Agents Chemother"},{"key":"3705_CR14","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.01242-13","volume":"58","author":"Macone","year":"2014","unstructured":"Macone AB, Caruso BK, Leahy RG et\u00a0al (2014) In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother 58:1127\u20131135","journal-title":"Antimicrob Agents Chemother"},{"key":"3705_CR15","unstructured":"Mazuski JE, Gasink L, Armstrong J (2015) Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection \u2013 results from a phase\u00a0III programme. 25th ECCMID, Kopenhagen. Abstract O191"},{"key":"3705_CR16","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1128\/AAC.02955-14","volume":"58","author":"Mensa","year":"2014","unstructured":"Mensa B, Howell GL, Scott R, DeGrado\u00a0WF (2014) Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob Agents Chemother 58:5136\u20135145","journal-title":"Antimicrob Agents Chemother"},{"key":"3705_CR17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.coph.2015.07.004","volume":"24","author":"Morata","year":"2015","unstructured":"Morata L, Mensa J, Soriano A (2015) New antibiotics against gram-positives: present and future indications. Curr Opin Pharmacol 24:45\u201345","journal-title":"Curr Opin Pharmacol"},{"key":"3705_CR18","doi-asserted-by":"crossref","unstructured":"Nathan C, Cars O (2014) Antibiotic resistance \u2013 problems, progress, and prospects. N\u00a0Engl J Med 371:1761\u20131763","DOI":"10.1056\/NEJMp1408040"},{"key":"3705_CR19","unstructured":"Oldach D, Barrera C, Mykietiuk A et\u00a0al (2015) SOLITAIRE-oral: results of a global phase\u00a03 trial comparing oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia (CABP) in adults. 25th ECCMID, Kopenhagen. Abstract LBOS0239c"},{"key":"3705_CR20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.coph.2014.09.008","volume":"18","author":"Page","year":"2014","unstructured":"Page MG, Bush K (2014) Discovery and development of new antibacterial agents targeting gram-negative bacteria in the era of pandrug resistance: is the future promising? Curr Opin Pharmacol 18:91\u201397","journal-title":"Curr Opin Pharmacol"},{"key":"3705_CR21","unstructured":"Ram S, Menon K, Scott RW et\u00a0al (2015) Synthetic novel host defense protein mimetics for the treatment of gram-negative bacterial infections. 25th ECCMID, Kopenhagen. Abstract O082"},{"key":"3705_CR22","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","volume":"60","author":"Solomkin","year":"2015","unstructured":"Solomkin J, Hershberger E, Miller B et\u00a0al (2015) Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase\u00a03 trial (ASPECT-cIAI). Clin Infect Dis 60:1462\u20131471","journal-title":"Clin Infect Dis"},{"key":"3705_CR23","unstructured":"Solomkin J, Slepavicius A, Evans D et\u00a0al (2015) Results of IGNITE1: a phase\u00a03 study to evaluate the efficacy and safety of eravacycline versus ertapenem in complicated intraabdominal infections. 25th ECCMID, Kopenhagen. Abstract LBOS0239d"},{"key":"3705_CR24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1164\/rccm.201410-1894OE","volume":"191","author":"Spellberg","year":"2015","unstructured":"Spellberg B, Bartlett J, Wunderink R, Gilbert\u00a0DN (2015) Novel approaches are needed to develop tomorrow\u2019s antibacterial therapies. Am J Respir Crit Care Med 191:135\u2013140","journal-title":"Am J Respir Crit Care Med"},{"key":"3705_CR25","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.01288-13","volume":"57","author":"Sutcliffe","year":"2013","unstructured":"Sutcliffe JA, O\u2019Brien W, Fyfe C, Grossman\u00a0TH (2013) Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother 57:5548\u20135558","journal-title":"Antimicrob Agents Chemother"},{"key":"3705_CR26","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s40265-014-0273-x","volume":"74","author":"Syed","year":"2014","unstructured":"Syed YY (2014) Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia. Drugs 74:1523\u20131542","journal-title":"Drugs"},{"key":"3705_CR27","unstructured":"Tsai L, Marsh A, Horn P, Lloyd\u00a0K (2015) Results of the lead-in study on the safety and efficacy of eravacycline versus levofloxacin in complicated urinary tract infections (cUTI). 25th ECCMID, Kopenhagen. Abstract O198"},{"key":"3705_CR28","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3109\/07853890.2014.935470","volume":"46","author":"Bambeke","year":"2014","unstructured":"Bambeke F van (2014) Renaissance of antibiotics against difficult infections: focus on oritavancin and new ketolides and quinolones. Ann Med 46:512\u2013529","journal-title":"Ann Med"},{"key":"3705_CR29","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","volume":"385","author":"Wagenlehner","year":"2015","unstructured":"Wagenlehner FM, Umeh O, Steenbergen J et\u00a0al (2015) Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase\u00a03 trial (ASPECT-cUTI). Lancet 385:1949\u20131956","journal-title":"Lancet"},{"key":"3705_CR30","doi-asserted-by":"crossref","unstructured":"Wang Y, Lv Y, Cai J et\u00a0al (2015) A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin. J\u00a0Antimicrob Chemother 70(8):2182\u20132190","DOI":"10.1093\/jac\/dkv116"},{"key":"3705_CR31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(14)71018-7","volume":"15","author":"Zhong","year":"2015","unstructured":"Zhong NS, Sun T, Zhuo C et\u00a0al (2015) Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase\u00a03, non-inferiority with nested superiority trial. Lancet Infect Dis 15:161\u2013171","journal-title":"Lancet Infect Dis"},{"key":"3705_CR32","unstructured":"http:\/\/www.chemspider.com\/"},{"key":"3705_CR33","unstructured":"https:\/\/pubchem.ncbi.nlm.nih.gov\/"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-015-3705-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-015-3705-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-015-3705-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T17:42:39Z","timestamp":1567273359000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-015-3705-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,18]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["3705"],"URL":"https:\/\/doi.org\/10.1007\/s00108-015-3705-0","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,18]]}}}